Table 3.
Main characteristics of the study patients with thromboembolic events
| Pt. ID | Age, years | Sex | CHA2DS2-VASc score | Previous stroke | Type of DOAC | Type of AED | Type of event | Fatal event | Time to event (days) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 75 | F | 4 | No | Rivaroxaban 20 mg |
Carbamazepine 400 mg bid |
Ischaemic stroke | No | 786 |
| 2 | 75 | F | 6 | Yes |
Apixaban 5 mg bid |
Valproic acid 500 mg |
TIA | No | 105 |
| 3 | 77 | F | 5 | Yes |
Apixaban 5 mg bid |
Levetiracetam 250 mg bid |
Ischaemic stroke | No | 17 |
| 4 | 81 | M | 5 | Yes |
Apixaban 5 mg bid |
Levetiracetam 500 bid |
Ischaemic stroke | No | 52 |
| 5 | 87 | F | 7 | Yes |
Apixaban 2.5 mg bid |
Carbamazepine 400 mg bid |
Ischaemic stroke | No | 947 |
| 6 | 90 | M | 2 | No | Rivaroxaban 15 mg |
Levetiracetam 500 mg bid |
Ischaemic stroke | No | 277 |
| 7 | 82 | M | 3 | No | Dabigatran 110 mg bid |
Levetiracetam 250 mg bid |
Ischaemic stroke | Yes | 655 |
| 8 | 88 | F | 8 | Yes | Rivaroxaban 15 mg |
Fenobarbital 100 mg + levetiracetam 250 mg bid |
Ischaemic stroke | Yes | 135 |
| 9 | 93 | F | 7 | Yes | Rivaroxaban 15 mg | Fenobarbital 100 mg | Ischaemic stroke | Yes | 71 |
AED anti-epileptic drug, DOAC direct oral anticoagulant, F female, M male, TIA transient ischaemic attack, bid twice daily